• 1
    Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-28s50.
  • 2
    Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352: 1138-1145.
  • 3
    NHLBI/NIDDK. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health: Bethesda, 1998.
  • 4
    Grodstein F, Levine R, Troy L, Spencer T, Colditz GA, Stampfer MJ. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch Intern Med 1996; 156: 1302-1306.
  • 5
    Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108 Suppl 6a: 15S-22S.
  • 6
    Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002; 4: 343-349.
  • 7
    Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-295.
  • 8
    Sinnayah P, Wallingford NM, Evans AE, Cowley MA. Bupropion and naltrexone interact synergistically to decrease food intake in mice. In: North American Association for the Study of Obesity Annual Scientific Meeting, New Orleans, LA 2007.
  • 9
    Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009; 17: 30-39.
  • 10
    Prescribing Information: Vivitrol (naltrexone for extended-release injectable suspension). 2010.
  • 11
    Prescribing Information: Zyban (bupropion hydrochloride) sustained-release tablets. 2012. pp 1-34.
  • 12
    Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94: 4898-4906.
  • 13
    Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
  • 14
    Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial. Obesity (Silver Spring) 2011; 19: 110-120.
  • 15
    World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004; 15: 124-129.
  • 16
    Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004; 57: 1153-1160.
  • 17
    Wilcox CS, Oskooilar N, Erickson JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010; 35: 229-234.
  • 18
    Rush AJ, Carmody TP, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research 2000; 9: 45-59.
  • 19
    SDI. Occurrences of bupropion prescriptions by BMI, Jan-Dec. 2009.
  • 20
    Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.
  • 21
    Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-161.
  • 22
    Volkow ND, Wise RA. How can drug addiction help us understand obesity? Nat Neurosci 2005; 8: 555-560.
  • 23
    Pelchat ML. Food cravings in young and elderly adults. Appetite 1997; 28: 103-113.
  • 24
    Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
  • 25
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
  • 26
    Health I. The National Disease and Therapeutic Index. Plymouth, PA, 1998-2003.